MOTS-c is a mitochondria-derived peptide that regulates energy metabolism by activating AMPK — the body's master fuel-sensing enzyme. It declines with age and physical inactivity, and research shows it improves metabolic flexibility, insulin sensitivity, and exercise endurance.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — not the nuclear genome like most peptides. It was first identified in 2015 and represents a class of "mitokines" — signaling molecules produced by mitochondria that communicate metabolic status to the rest of the body. MOTS-c is found in blood, muscle, and plasma, and its levels are significantly higher in young, physically active individuals and lower in older, sedentary, or metabolically compromised ones. It is increasingly understood as a restoration of a natural protective signaling system that declines with aging.
Mechanism of Action
MOTS-c activates AMPK (5' AMP-activated protein kinase) — the master energy-sensing enzyme that regulates glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and cellular energy homeostasis. It enters the nucleus under conditions of metabolic stress, where it regulates the expression of genes involved in one-carbon metabolism and the folate cycle — pathways central to NAD+ production, amino acid synthesis, and epigenetic regulation. MOTS-c also improves insulin sensitivity by enhancing glucose uptake in muscle cells independently of the insulin receptor signaling pathway, which is relevant to insulin resistance. In aging models, MOTS-c supplementation reverses diet-induced insulin resistance and improves physical endurance.
Key Research
MOTS-c was identified by Cohen lab at USC (Lee et al., 2015, Cell Metabolism). Subsequent research confirmed MOTS-c declines with age in humans and is elevated by exercise — specifically associated with the metabolic benefits of physical activity. Animal studies showed MOTS-c prevents diet-induced obesity and metabolic syndrome, reverses insulin resistance, and extends healthy lifespan in aged mice. Human observational data links higher circulating MOTS-c to better metabolic health, lower BMI, and reduced type 2 diabetes risk in aging populations. Exercise studies documented MOTS-c as a mediator of exercise-induced metabolic adaptation. Pre-clinical studies demonstrated MOTS-c administration increases exercise endurance by 40–60% in rodent models.
Research dosing is typically 5–10 mg subcutaneously, administered 3–5 times per week. Effects on metabolic markers build over 2–4 weeks of consistent use. Both rest-day and training-day administration contribute to metabolic adaptation — MOTS-c is not a purely acute compound. Cycle: 10–16 weeks on / 4–6 weeks off. Often combined with Humanin (the other major mitokine) and/or Tesamorelin for comprehensive metabolic optimization.
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
MOTS-c is well tolerated in all research models to date with no identified toxicity. Injection site discomfort is mild. Because MOTS-c activates AMPK — which broadly improves cellular energy sensing — hypoglycemia is a theoretical concern in individuals already on insulin or other hypoglycemic agents. Blood glucose monitoring is prudent in those populations. No endocrine suppression, hepatotoxicity, or organ damage has been documented. As a naturally occurring peptide encoded in the mitochondrial genome, its safety profile is considered favorable.
Storage & Handling
Store lyophilized MOTS-c at -20°C for long-term storage. Stable at 2–8°C for up to 1 month. Reconstitute with bacteriostatic water and use within 28 days when refrigerated. Protect from light and repeated temperature cycling. MOTS-c is considered moderately stable in solution.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
